Jonathan Friedberg: End Point Surrogacy in First-Line CLL
Jonathan Friedberg, Director of Wilmot Cancer Institute, posted the following on X:
“End Point Surrogacy in First-Line CLL: Given the clear PFS benefit in patients who achieve undetectable MRD after therapy, novel strategies incorporating MRD as an endpoint are ready for evaluation as a precision approach to CLL therapy. JCO ASCO”
End Point Surrogacy in First-Line Chronic Lymphocytic Leukemia
Authors: Florian Simon, MD, Rudy Ligtvoet, PhD, Sandra Robrecht, PhD, Paula Cramer, MD, Nadine Kutsch, MD, Moritz Fürstenau, MD, Valentin Goede, MD, Julia von Tresckow, MD, Petra Langerbeins, MD, Anna-Maria Fink, MD, Henriette Huber, MD, Eugen Tausch, MD, Christof Schneider, MD, Clemens M. Wendtner, MD, Matthias Ritgen, MD, Martin Dreyling, MD, Lothar Müller, MD, Lutz Jacobasch, MD, Werner J. Heinz, MD, Ursula Vehling-Kaiser, MD, Liliya Sivcheva, MD, Sebastian Böttcher, MD, Peter Dreger, MD, Thomas Illmer, MD, Michael Gregor, MD, Philipp B. Staber, MD, Stephan Stilgenbauer, MD, Carsten U. Niemann, MD, Arnon P. Kater, MD, Kirsten Fischer, MD, Barbara Eichhorst, MD, Michael Hallek, MD, Othman Al-Sawaf, MD.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023